Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
|Slideshows|September 3, 2019
7 New Looks into COPD
Author(s)Leo Robert
Can air pollution cause emphysema? Can yoga positively impact lung function? New research has answers to these questions plus 5 more.
Advertisement
Air pollution precipitates emphysema progression, vaping elevates chronic lung disease risk, yoga may be beneficial in improving lung function-these are some of the latest developments in chronic obstructive pulmonary disease (COPD) research. Scroll through the slides below to find concise summaries of key points for clinical practice.Â
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
Individualizing Obesity Treatment in Primary Care: An Expert Discussion
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5